3-year fixed-term contract, full time. Start date: April 2021.
Background. Diffuse gliomas are the most frequent and most dismal primary brain tumours in adults. Gliomas undergo cellular and molecular evolution during disease progression, which is only partially explained by genetic evolution, suggesting that transcriptional and epigenetic changes may be the basis of cellular adaptation processes. The international GLASS (Glioma Longitudinal AnalySiS) initiative, aims to systematically catalogue the temporal changes in gliomas at the genetic, epigenetic and transcriptomic levels. In this context, NORLUX aims to assess differential functional drug responses of primary versus recurrent gliomas.
Objectives. By combining mulitomics molecular characterisation and high content drug screens on ex vivo patient-derived glioma organoids from paired longitudinal tumors, we aim to determine differences in drug sensitivity and predict personalized treatment options for recurrent glioma patients. Patient-derived orthotopic xenografts (PDOX) will be applied for in vivo validation studies.
Training and research environment. The NORLUX lab is a dynamic, multinational and interdisciplinary team focusing on the biology of malignant brain cancer. It is part of the Department of Oncology and uses cutting edge technologies, including genomic, metabolomic and proteomic analyses, single cell technologies (single cell RNA-Seq, CYTOF, Imagestream) as well as state-of-the-art preclinical models. The project will be performed in collaboration with the international GLASS consortium (www.glass-consortium.org/). The post-doctoral fellow will be supported through a FNR CORE funded project and will join an interdisciplinary project team, including cellular and molecular biologists, animal experts, bioinformaticians and statisticians. Recent related reference: https://pubmed.ncbi.nlm.nih.gov/33009951/
Key Skills, Experience and Qualifications
- PhD in Molecular Biology or Biomedical Sciences with experience in cancer research.
- Experience in molecular biology and genome-wide molecular profiling is required. Previous experience in drug screening, epigenetics (ATAC-seq), multi-omics analyses and imaging is desirable.
- Animal experimentation diploma (FELASA or equivalent) will be an asset.
- Independent and self-motivated person, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigor, perseverance, strong writing skills.
- Fluency in English is mandatory.
Researchers are supported by easy access to scientific expertise, well-equipped facilities, an active seminar program as well as opportunities for conference attendance and collaborations with other research organisations.
Prof Simone Niclou, PhD
84 Val Fleuri
More information about the group can be found here : https://norlux.lih.lu
Applications including a cover letter and curriculum vitae should be sent before 1st February 2021 through our website www.lih.lu/jobs : CM/PDPG1220/SN/Norlux